Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Golvatinib (E7050) restores chemosensitivity in multidrug-resistant cancer cells by inhibiting ABCG2 transporter.
Journal: Pathology, research and practice
Published: July 03, 2026
3D Spheroid Model: A Methodological Approach for Advancing Cancer and Immunology Research.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: January 01, 2026
Cancer neuroscience: illuminating the neural dimension of tumor biology.
Journal: Scientific reports
Published: December 23, 2025
Striking at Survivin: YM-155 Inhibits High-Risk Neuroblastoma Growth and Enhances Chemosensitivity.
Journal: Cancers
Published: September 08, 2025
Direct Targeting of CXCR2 Receptor Inhibits Neuroblastoma Growth: An In Vitro Assessment.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: September 04, 2025
STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: August 11, 2025
Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 28, 2024
CAMKV Kinase Signaling Is a Novel Therapeutic Avenue with Prognostic Relevance in Neuroblastoma.
Journal: bioRxiv : the preprint server for biology
Published: February 22, 2024
Pediatric Cancers: Insights and Novel Therapeutic Approaches.
Journal: Cancers
Published: June 28, 2023
ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo.
Journal: Cancers
Published: September 28, 2022
Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth.
Journal: Current oncology (Toronto, Ont.)
Published: August 15, 2022
Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 21, 2022
Last Updated: 09/26/2026